Tissuepathology.com

HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases

Erica Goodpaster — Tue, 20 Oct 2026 12:52:38 +0000

[SINGAPORE, October 19th, 2026] – /PR Newswire/ HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to collaborate on the preclinical evaluation and characterization of therapeutic candidates for various fibrotic diseases, including […]

The post HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases first appeared on Tissuepathology.com.

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Erica Goodpaster — Mon, 19 Oct 2026 12:41:31 +0000

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer (NSCLC). The panel […]

The post Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC first appeared on Tissuepathology.com.

Deciphex CEO at International AI Summit in Dublin

Erica Goodpaster — Fri, 16 Oct 2026 11:51:30 +0000

From Deciphex on LinkedIn: Our founder and CEO Donal O’Shea was on stage at the International AI Summit in Dublin yesterday, the flagship AI event of Ireland’s EU Council Presidency. He joined Áine Kerr, Dorothy Creaven (Jentic), Eoin Hinchy (Tines) and Guillaume Princen (Anthropic) on the panel “Developing Global AI Leaders: From Start-ups to Scale-ups”. […]

The post Deciphex CEO at International AI Summit in Dublin first appeared on Tissuepathology.com.

Indica Labs and NeoGenomics Expand AI Leadership Through Enterprise Digital Pathology Partnership

Erica Goodpaster — Fri, 16 Oct 2026 11:41:44 +0000

ALBUQUERQUE, N.M, October 15, 2026 — Indica Labs, the trusted global leader in AI-powered digital pathology, today announced a significant expansion of its strategic partnership with NeoGenomics, a leading provider of oncology diagnostic solutions that enable precision medicine. The expanded collaboration is intended to modernize NeoGenomics enterprise digital pathology infrastructure, accelerate the evaluation and adoption […]

The post Indica Labs and NeoGenomics Expand AI Leadership Through Enterprise Digital Pathology Partnership first appeared on Tissuepathology.com.

Aiforia sets a new benchmark with the release of Aiforia® Create 8.0

Erica Goodpaster — Thu, 15 Oct 2026 15:31:04 +0000

Aiforia® Create 8.0 makes AI model development even faster, smoother, and more intuitive than before. Aiforia Technologies Plc today announces the global market release of Aiforia® Create version 8.0, setting a new industry standard for AI model development in digital pathology. Designed for pathologists, researchers, and other domain experts, Aiforia® Create is the most versatile […]

The post Aiforia sets a new benchmark with the release of Aiforia® Create 8.0 first appeared on Tissuepathology.com.

OptraSCAN to Unveil the FDA-Cleared OS-Ultra Scanner at Pathology Visions 2026

Erica Goodpaster — Wed, 14 Oct 2026 13:19:59 +0000

OptraSCAN: The whole slide scanner will make its first public appearance at booth 417, following its clearance. Available starting in December. SAN JOSE, CA, UNITED STATES, October 13, 2026 /EINPresswire.com/ — SAN JOSE, Calif., Oct. 13, 2026 — OptraSCAN, Inc. today announced it will unveil the FDA-cleared OS-Ultra whole slide scanner at the Digital Pathology […]

The post OptraSCAN to Unveil the FDA-Cleared OS-Ultra Scanner at Pathology Visions 2026 first appeared on Tissuepathology.com.